Inventor · disambiguated record
Aaron Edward Foster
Also filed as: FOSTER AARON · FOSTER AARON E · FOSTER AARON EDWARD · FOSTER SR AARON EDWARD
7 granted patents·18 pending applications·48 citations·filing 2011–2023
84Inventor score
Files withBELLICUM PHARMACEUTICALS INC19SANA BIOTECHNOLOGY INC3BELLICUM PHARMACEUTICS INC1FOSTER AARON E1UNIV TEXAS1
Top patents by PatentIndex Score
25 records- 0193US10888608B2Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2015·Granted Jan 12, 2021·8 cites·16 claims
- 0290US9913882B2Methods for inducing partial apoptosis using caspase polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2014·Granted Mar 13, 2018·16 cites·57 claims
- 0389US9944690B2Methods for controlling T cell proliferationBELLICUM PHARMACEUTICALS INC·Filed 2014·Granted Apr 17, 2018·14 cites·15 claims
- 0485US10525110B2Methods for inducing partial apoptosis using caspase polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2018·Granted Jan 7, 2020·4 cites·33 claims
- 0583US10918705B2Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2020·Granted Feb 16, 2021·1 cites·22 claims
- 0680US10934346B2Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12BELLICUM PHARMACEUTICALS INC·Filed 2015·Granted Mar 2, 2021·5 cites·15 claims
- 0769US2024368574A1Dual controls for therapeutic cell activation or eliminationUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0867US11839647B2Methods for inducing partial apoptosis using caspase polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2020·Granted Dec 12, 2023·0 cites·25 claims
- 0965US2021346477A1Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptidesBELLICUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1065US2025222027A1Cytokine receptor agonist and viral vector combination therapiesSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1164US2025082777A1Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and usesSANA BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 1260US2022062338A1Psca car-t cellsBELLICUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1357US2022125837A1Methods for controlled elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1456US2022152100A1Methods for controlled activation or elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1555US2022025024A1Methods for activating t cells using an inducible chimeric polypeptideBELLICUM PHARMACEUTICS INC·Filed 2021·Application pending·0 cites
- 1655US2023065562A1Dual controls for therapeutic cell activation or eliminationBELLICUM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1754US2024344083A1Use of cd4-targeted viral vectorsSANA BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 1850US2020347148A1Methods for enhancing and maintaining car-t cell efficacyBELLICUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1949US2018265566A1Methods for controlling t cell proliferationBELLICUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2048US2022002674A1T cells with suicide switchBELLICUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2144US2021147507A1Methods to augment or alter signal transductionBELLICUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2241US2017166877A1Dual controls for therapeutic cell activation or eliminationBELLICUM PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2341US2014086828A1Modified gold nanoparticles for therapyFOSTER AARON E·Filed 2011·Application pending·0 cites
- 2437US2016166613A1Methods for controlled elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2535US2016175359A1Methods for controlled activation or elimination of therapeutic cellsBELLICUM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Aaron Edward Foster files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →